drugset / Trial / NCT03984370

Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass

NCT03984370

Phase 2 Completed 10 enrolled University Hospital, Gentofte, Copenhagen
RandomizedCrossoverDouble-blindTreatment

Summary

The aim of this study is investigating the effect of a novel glucagon analogue administration in gastric bypass operated individuals, who are reactive hypoglycemic.

Timeline

Start
2019-09-18
Primary completion
2020-02-26
Completion
2020-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Dasiglucagon Peptide 80 ug Subcutaneous
Subject Dasiglucagon Peptide 200 ug Subcutaneous